查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529764

结缔组织疾病市场规模、份额、趋势分析报告：按疾病、药物、分销管道、地区和细分市场预测，2024-2030年

Connective Tissue Disease Market Size, Share & Trends Analysis Report By Disease (Rheumatoid Arthritis), By Drug (Pharmaceuticals), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

结缔组织疾病市场趋势

2023年，结缔组织疾病的全球市场规模预计为240.4亿美元，预计2024年至2030年复合年增长率为6.1%。这种增长是由于这些疾病的盛行率不断增加、诊断技术和治疗方法的进步以及对有效治疗的需求不断增加。类风湿性关节炎、全身性红斑性狼疮红斑狼疮和硬皮症自体免疫疾病和风湿性疾病的盛行率不断上升，是结缔组织疾病 (CTD) 市场成长的关键驱动力。根据美国的数据，大约 150 万美国和超过 500 万人患有某种形式的狼疮。

此外，世界人口老化也是推动市场的因素之一。随着年龄的增长，我们更有可能患上类风湿性关节炎和硬皮症等自体免疫疾病。这种人口趋势正在推动对创新趋势和个人化医疗的需求，以满足患有结缔组织疾病的老年患者的独特需求。製药公司正在投资研发工作，以推出针对这些疾病的新治疗方法。

此外，精准医学和生物标记发现的技术进步正在改变结缔组织疾病的诊断和治疗模式。旨在调节参与自体免疫反应的特定途径的标靶治疗的出现正在推动市场成长。例如，正在开发单株抗体等生物製药，以靶向CTD发病机制中涉及的关键分子，为患者提供更有效、更安全的治疗选择。这些创新透过提供改善患者治疗效果和生活品质的个人化解决方案正在再形成市场。

结缔组织疾病全球市场区隔报告

该报告预测了全球、区域和国家层面的收益成长，并对2018年至2030年各子区隔的最新行业趋势进行了分析。在这项研究中，Grand View Research 根据疾病、药物、分销管道和地区对全球结缔组织病市场报告进行了细分：

  • 结缔组织疾病展望（销售，2018-2030）。
  • 类风湿性关节炎（RA）。
  • 全身性红斑性狼疮（SLE）。
  • 硬皮症。
  • 多发性肌炎。
  • 皮肌炎。
  • 修格兰氏症候群。
  • 混合结缔组织疾病（MCTD）。
  • 未分化结缔组织疾病（UCTD）。
  • 其他结缔组织疾病。
  • 结缔组织疾病治疗药物展望（销售额，2018-2030）。
  • 医药产品。

非类固醇消炎剂(NSAID)

缓解疾病抗风湿药物 (DMARD)

皮质类固醇

其他药品

  • 生物製药

生技药品

肿瘤坏死因子抑制剂

IL-6抑制剂

B细胞抑制剂

T细胞抑制剂

其他生技药品

生物相似药

  • 结缔组织疾病通路展望（销售额，2018-2030）。
  • 医院药房。
  • 零售药房。
  • 网上药局。
  • 区域展望（收益，2018-2030）。
  • 北美。

美国。

加拿大

墨西哥

  • 欧洲

英国

德国

法国

义大利

西班牙

丹麦

瑞典

挪威

  • 亚太地区

日本

中国

印度

澳洲

韩国

泰国

  • 拉丁美洲

巴西

阿根廷

  • 中东/非洲

南非

沙乌地阿拉伯

阿拉伯聯合大公国

科威特

目录

第一章调查方法与范围

第 2 章执行摘要

第三章结缔组织疾病市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 结缔组织疾病市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 管道分析

第四章结缔组织疾病市场：疾病估计与趋势分析

  • 全球结缔组织疾病市场：疾病仪表板
  • 全球结缔组织疾病市场：疾病分析
  • 按疾病和收益的全球结缔组织疾病市场
  • 类风湿性关节炎（RA）
  • 全身性红斑性狼疮（SLE）
  • 硬皮症
  • 多发性肌炎
  • 皮肌炎
  • 修格兰氏症候群
  • 混合结缔组织疾病 (MCTD)
  • 未分化结缔组织疾病（UCTD）
  • 其他结缔组织疾病

第五章结缔组织疾病市场：药品估计与趋势分析

  • 全球结缔组织疾病市场：製药仪表板
  • 全球结缔组织疾病市场：药品波动分析
  • 按药品分類的收益
  • 药品
  • 生物製药

5.5.2.2.1.1. 2018-2030 年 TNF 抑制剂市场估计与预测

5.5.2.3.1.1. 2018-2030 年 IL-6 抑制剂市场估计与预测

5.5.2.4.1.1. 2018-2030 年 B 细胞抑制剂市场估计与预测

5.5.2.5.1.1. 2018-2030 年 T 细胞抑制剂市场估计与预测

5.5.2.6.1.1. 2018-2030 年其他生技药品市场估计与预测

  • 生物相似药
    • 2018-2030 年生物相似药市场估计与预测

第六章结缔组织疾病市场：通路估计与趋势分析

  • 全球结缔组织疾病市场：分销通路仪表板
  • 全球结缔组织病市场：通路波动分析
  • 按分销管道分類的收益
  • 医院药房
  • 零售药房
  • 网路药房

第七章结缔组织疾病市场：按疾病、药物和分销管道分類的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第八章 竞争格局

  • 公司/竞争对手分类
  • 供应商情况
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • AbbVie, Inc.
    • Amgen, Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Johnson &Johnson Services, Inc.
    • Lily
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc.
    • UCB SA
Product Code: GVR-4-68040-348-8

Connective Tissue Disease Market Trends

The global connective tissue disease market size was estimated at USD 24.04 billion in 2023 and is expected to grow at a CAGR of 6.1% from 2024 to 2030. This growth is attributed to the increasing prevalence of these diseases, advancements in diagnostic techniques & treatment approaches, and growing demand for effective treatments. The rising incidence of autoimmune and rheumatic disorders, such as rheumatoid arthritis, systemic lupus erythematosus, and scleroderma, is a significant driver for the growth of the connective tissue disease (CTD) market. According to the Lupus Foundation of America,about 1.5 million Americans and more than five million people globally are affected by some type of lupus.

Moreover, the aging population worldwide is another significant driver for the growth of the market. As individuals age, they are more prone to developing autoimmune disorders such as rheumatoid arthritis and scleroderma, both of which fall under the category of connective tissue disease. This demographic trend fuels the demand for innovative therapies and personalized medicine approaches tailored to address the specific needs of elderly patients with connective tissue diseases. Pharmaceutical companies invest in research and development activities to introduce novel treatments targeting these conditions.

Furthermore, technological advancements in precision medicine and biomarker discovery are revolutionizing the diagnosis and treatment landscape for connective tissue diseases. The emergence of targeted therapies that aim to modulate specific pathways involved in autoimmune responses is propelling market growth. For instance, biologics such as monoclonal antibodies are being developed to target key molecules implicated in CTD pathogenesis, offering patients more effective and safer treatment options. These innovations are reshaping the market by providing personalized solutions that improve patient outcomes and quality of life.

Global Connective Tissue Disease Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global connective tissue disease market report on the basis of disease, drug, distribution channel, region:

  • Connective Tissue Disease Outlook (Revenue, USD Million, 2018 - 2030)
  • Rheumatoid Arthritis (RA)
  • Systemic Lupus Erythematosus (SLE)
  • Scleroderma
  • Polymyositis
  • Dermatomyositis
  • Sjogren's Syndrome
  • Mixed Connective Tissue Disease (MCTD)
  • Undifferentiated Connective Tissue Disease (UCTD)
  • Other connective tissue disease
  • Connective Tissue Disease Drug Outlook (Revenue, USD Million, 2018 - 2030)
  • Pharmaceuticals

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Corticosteroids

Other Pharmaceuticals

  • Biopharmaceuticals

Biologics

TNF Inhibitors

IL-6 Inhibitors

B-cell Inhibitors

T-cell Inhibitors

Other Biologics

Biosimilars

  • Connective Tissue Disease Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

  • Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

  • Latin America

Brazil

Argentina

  • Middle East and Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Drug
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease outlook
    • 2.2.2. Drug outlook
    • 2.2.3. Distribution Channel outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Connective Tissue Disease Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of connective tissue diseases
      • 3.2.1.2. Aging Population
      • 3.2.1.3. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High treatment cost
  • 3.3. Connective Tissue Disease Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Connective Tissue Disease Market: Disease Estimates & Trend Analysis

  • 4.1. Global Connective Tissue Disease Market: Disease Dashboard
  • 4.2. Global Connective Tissue Disease Market: Disease Analysis
  • 4.3. Global Connective Tissue Disease Market by Disease, Revenue
  • 4.4. Rheumatoid Arthritis (RA)
    • 4.4.1. Rheumatoid Arthritis (RA) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Systemic Lupus Erythematosus (SLE)
    • 4.5.1. Systemic Lupus Erythematosus (SLE) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Scleroderma
    • 4.6.1. Scleroderma market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Polymyositis
    • 4.7.1. Polymyositis market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Dermatomyositis
    • 4.8.1. Dermatomyositis market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Sjogren's Syndrome
    • 4.9.1. Postpartum psychosis market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Mixed Connective Tissue Disease (MCTD)
    • 4.10.1. Mixed Connective Tissue Disease (MCTD) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.11. Undifferentiated Connective Tissue Disease (UCTD)
    • 4.11.1. Undifferentiated Connective Tissue Disease (UCTD) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.12. Other connective tissue disease
    • 4.12.1. Other connective tissue disease market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Connective Tissue Disease Market: Drug Estimates & Trend Analysis

  • 5.1. Global Connective Tissue Disease Market: Drug Dashboard
  • 5.2. Global Connective Tissue Disease Market: Drug Movement Analysis
  • 5.3. Global Connective Tissue Disease Market Estimates and Forecasts, By Drug, Revenue (USD Million)
  • 5.4. Pharmaceuticals
    • 5.4.1. Pharmaceuticals market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
      • 5.4.2.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
      • 5.4.3.1. Disease-Modifying Anti-Rheumatic Drugs (DMARDs) market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Corticosteroids
      • 5.4.4.1. Corticosteroids market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Other Pharmaceuticals
      • 5.4.5.1. Other Pharmaceuticals market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Biopharmaceuticals
    • 5.5.1. Biopharmaceuticals market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Biologics
      • 5.5.2.1. Biologics market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.5.2.2. TNF Inhibitors

5.5.2.2.1.1. TNF Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

      • 5.5.2.3. IL-6 Inhibitors

5.5.2.3.1.1. IL-6 Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

      • 5.5.2.4. B-cell Inhibitors

5.5.2.4.1.1. B-cell Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

      • 5.5.2.5. T-cell inhibitors

5.5.2.5.1.1. T-cell Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

      • 5.5.2.6. Other Biologics

5.5.2.6.1.1. Other Biologics market estimates and forecasts 2018 to 2030 (USD Million)

  • 5.6. Biosimilars
    • 5.6.1. Biosimilars market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Connective Tissue Disease Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global Connective Tissue Disease Market: Distribution Channel Dashboard
  • 6.2. Global Connective Tissue Disease Market: Distribution Channel Movement Analysis
  • 6.3. Global Connective Tissue Disease Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Connective Tissue Disease Market: Regional Estimates & Trend Analysis by Disease, Drug, and Distribution Channel

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Vendor Landscape
    • 8.2.1. List of key distributors and channel partners
    • 8.2.2. Key customers
    • 8.2.3. Key company market share analysis, 2023
    • 8.2.4. AbbVie, Inc.
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Amgen, Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Boehringer Ingelheim International GmbH
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Bristol-Myers Squibb Company
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. F. Hoffmann-La Roche Ltd.
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Johnson & Johnson Services, Inc.
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Lily
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
    • 8.2.11. Novartis AG
      • 8.2.11.1. Company overview
      • 8.2.11.2. Financial performance
      • 8.2.11.3. Product benchmarking
      • 8.2.11.4. Strategic initiatives
    • 8.2.12. Pfizer Inc.
      • 8.2.12.1. Company overview
      • 8.2.12.2. Financial performance
      • 8.2.12.3. Product benchmarking
      • 8.2.12.4. Strategic initiatives
    • 8.2.13. Regeneron Pharmaceuticals Inc.
      • 8.2.13.1. Company overview
      • 8.2.13.2. Financial performance
      • 8.2.13.3. Product benchmarking
      • 8.2.13.4. Strategic initiatives
    • 8.2.14. UCB S.A.
      • 8.2.14.1. Company overview
      • 8.2.14.2. Financial performance
      • 8.2.14.3. Product benchmarking
      • 8.2.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 4 North America Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 5 North America Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 7 U.S. Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 8 U.S. Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Canada Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 10 Canada Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 11 Canada Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Mexico Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 13 Mexico Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 14 Mexico Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 17 Europe Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 18 Europe Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Germany Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 20 Germany Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 21 Germany Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 UK Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 23 UK Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 24 UK Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 France Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 26 France Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 27 France Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Italy Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 29 Italy Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 30 Italy Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Spain Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 32 Spain Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 33 Spain Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Denmark Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 35 Denmark Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 36 Denmark Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Sweden Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 38 Sweden Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 39 Sweden Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Norway Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 41 Norway Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 42 Norway Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 China Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 48 China Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 49 China Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Japan Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 51 Japan Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 52 Japan Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 India Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 54 India Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 55 India Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 South Korea Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 57 South Korea Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 58 South Korea Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 Australia Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 60 Australia Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 61 Australia Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Thailand Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 63 Thailand Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 64 Thailand Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 Latin America Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
  • Table 66 Latin America Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 67 Latin America Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 68 Latin America Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 Brazil Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 70 Brazil Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 71 Brazil Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 72 Argentina Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 73 Argentina Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 74 Argentina Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 MEA Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 77 MEA Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 78 MEA Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 South Africa Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 80 South Africa Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 81 South Africa Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85 UAE Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 86 UAE Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 87 UAE Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Connective Tissue Disease market: market outlook
  • Fig. 14 Connective Tissue Disease competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Connective Tissue Disease market driver impact
  • Fig. 18 Connective Tissue Disease market restraint impact
  • Fig. 19 Connective Tissue Disease market: Disease movement analysis
  • Fig. 20 Connective Tissue Disease market: Disease outlook and key takeaways
  • Fig. 21 Rheumatoid Arthritis (RA) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Systemic Lupus Erythematosus (SLE) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Scleroderma market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Polymyositis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Dermatomyositis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Sjogren's Syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Mixed Connective Tissue Disease (MCTD) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Undifferentiated Connective Tissue Disease (UCTD) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Other connective tissue diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Connective Tissue Disease market: Drug movement analysis
  • Fig. 31 Connective Tissue Disease market: Drug outlook and key takeaways
  • Fig. 32 Pharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Disease-Modifying Anti-Rheumatic Drugs (DMARDs) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Biopharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Biologics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 TNF Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 IL-6 Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 B-cell Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 T-cell Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Other Biologics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Biosimilars market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Connective Tissue Disease market: Distribution channel movement analysis
  • Fig. 46 Connective Tissue Disease market: Distribution channel outlook and key takeaways
  • Fig. 47 Hospital Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Retail Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Online Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Global Connective Tissue Disease market: Regional movement analysis
  • Fig. 51 Global Connective Tissue Disease market: Regional outlook and key takeaways
  • Fig. 52 Global Connective Tissue Disease market share and leading players
  • Fig. 53 North America, by country
  • Fig. 54 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 U.S. key country dynamics
  • Fig. 56 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Canada key country dynamics
  • Fig. 58 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Mexico key country dynamics
  • Fig. 60 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 UK key country dynamics
  • Fig. 63 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Germany key country dynamics
  • Fig. 65 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 France key country dynamics
  • Fig. 67 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Italy key country dynamics
  • Fig. 69 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Spain key country dynamics
  • Fig. 71 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Denmark key country dynamics
  • Fig. 73 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Sweden key country dynamics
  • Fig. 75 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Norway key country dynamics
  • Fig. 77 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 China key country dynamics
  • Fig. 80 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Japan key country dynamics
  • Fig. 82 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 India key country dynamics
  • Fig. 84 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Thailand key country dynamics
  • Fig. 86 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 South Korea key country dynamics
  • Fig. 88 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Australia key country dynamics
  • Fig. 90 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Brazil key country dynamics
  • Fig. 93 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Argentina key country dynamics
  • Fig. 95 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 South Africa key country dynamics
  • Fig. 98 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Saudi Arabia key country dynamics
  • Fig. 100 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 UAE key country dynamics
  • Fig. 102 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Kuwait key country dynamics
  • Fig. 104 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Market share of key market players - Connective Tissue Disease market